- Home
- TGHL vs APRE Comparison
TGHL vs APRE Comparison
Compare TGHL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | APRE |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TGHL | APRE |
|---|---|---|
| Price | $0.40 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 29.5K | ★ 416.4K |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.55 |
| 52 Week High | $3.80 | $2.22 |
Technical Indicators
Market Signals| Indicator | TGHL | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 65.64 |
| Support Level | $0.33 | $0.90 |
| Resistance Level | $0.38 | $1.53 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 60.09 | 76.01 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.